Evotec's chief scientific officer Cord Dohrmann to step down September 30, 2026
Evotec SE said Dr. Cord Dohrmann will leave his role by mutual consent, with a search underway for his successor.
SEC filing
Latest
2 stories
Tuesday, September 29
Wednesday, September 9
Evotec's Just biologics unit starts Phase 1 trial of antibody cocktail against orthopoxviruses
JST-018, developed for the U.S. Department of War's Accelerated Antibodies Program, moves into first-in-human testing after manufacturing at Evotec's Redmond facility.
SEC filing